Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

The weight loss drug company continues to make progress, but its share price is bouncing around with events.

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

Published October 2, 2026 · Category: Finance

Overview

Viking Therapeutics (NASDAQ: VKTX) stock soared after the release of excellent top-line results from a maintenance study of its weight-loss drug VK2735, and the company promptly moved to ultimately raise $575 million via a supplementary public offering of common stock ($316.2 million worth at $35) and $258.8 million in convertible senior notes. However, the stock now trades below the $35 price of this latest common equity offering. Is it worth buying?

On balance, the answer is: If you were bullish on the stock before the top-line results came out, it makes sense to buy it now, too.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.